Autolus Therapeutics (AUTL) Q3 2024 earnings summary

Executive summary

• FDA approved AUCATZYL (obecabtagene autoleucel) for adult relapsed/refractory B-cell ALL in the US on November 8, 2024, marking the first CAR-T therapy for ALL approved without a REMS requirement; US commercial launch initiated and regulatory reviews ongoing in Europe and the UK.

• 30 treatment centers are ready for activation, covering 60% of the US relapsed/refractory ALL population, with plans to expand to 60 centers and 90% coverage in 2025.

• Commercial manufacturing facility, the Nucleus, supports up to 2,000 products annually, targeting a 16-day release time.

• Product priced at $525,000, reflecting value, clinical evidence, and safety profile to ensure broad coverage and access.

• Matthias Will, M.D., appointed Chief Development Officer, effective September 30, 2024.

Financial highlights

• Cash and cash equivalents at September 30, 2024, were $657.1 million, up from $239.6 million at December 2023.

• Net loss for Q3 2024 was $82.1 million, compared to $45.8 million in Q3 2023; net loss for the nine months ended September 30, 2024, was $193.1 million.

• R&D expenses increased to $40.3 million in Q3 2024, mainly due to higher salaries and Obe-Cel clinical/manufacturing costs.

• G&A expenses rose to $27.3 million in Q3 2024, driven by increased headcount for commercialization and launch readiness.

• Raised $520.6 million in equity in Q1 2024, including $193.8 million from BioNTech and $326.8 million from an underwritten offering.

Outlook and guidance

• Sufficient cash runway to support full US launch and commercialization of Obe-Cel in adult ALL and advance pipeline, including pivotal autoimmune studies.

• Initial SLE Phase 1 data expected by end of Q1 2025, with longer-term follow-up and pediatric ALL data in the second half of 2025.

• Additional clinical activity and data updates planned throughout 2025.

• European and UK regulatory approvals for Obe-Cel anticipated by mid-2025.